|(what is this?)|
Dermatan sulfate accumulates abnormally in several of the mucopolysaccharidosis disorders.
An excess of dermatan sulfate in the mitral valve is characteristic of myxomatous degeneration of the leaflets leading to redundancy of valve tissue and ultimately, mitral valve prolapse (into the left atrium) and insufficiency. This chronic prolapse occurs mainly in women over the age of 60, and can predispose the patient to mitral annular calcification. Mitral valve insufficiency can lead to eccentric (volume dependent or dilated) hypertrophy and eventually left heart failure if untreated.
- Trowbridge, JM; Gallo, RL (September 2002). "Dermatan sulfate: new functions from an old glycosaminoglycan". Glycobiology 12 (9): 117R–25R. doi:10.1093/glycob/cwf066. PMID 12213784.
- Janet M. Trowbridge and Richard L. Gallo (2002). "Dermatan sulfate: new functions from an old glycosaminoglycan". Glycobiology 12 (9): 117R–125R. doi:10.1093/glycob/cwf066. PMID 12213784.
|This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.|
|This biochemistry article is a stub. You can help Wikipedia by expanding it.|